Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Differences in HIV-specific T cell responses between HIV-exposed and -unexposed HIV-seronegative individuals.

Ritchie AJ, Campion SL, Kopycinski J, Moodie Z, Wang ZM, Pandya K, Moore S, Liu MK, Brackenridge S, Kuldanek K, Legg K, Cohen MS, Delwart EL, Haynes BF, Fidler S, McMichael AJ, Goonetilleke N.

J Virol. 2011 Apr;85(7):3507-16. doi: 10.1128/JVI.02444-10. Epub 2011 Jan 26.

2.

Identification and antigenicity of broadly cross-reactive and conserved human immunodeficiency virus type 1-derived helper T-lymphocyte epitopes.

Wilson CC, Palmer B, Southwood S, Sidney J, Higashimoto Y, Appella E, Chesnut R, Sette A, Livingston BD.

J Virol. 2001 May;75(9):4195-207.

3.

Low-level exposure to HIV induces virus-specific T cell responses and immune activation in exposed HIV-seronegative individuals.

Restrepo C, Rallón NI, del Romero J, Rodríguez C, Hernando V, López M, Peris A, Lozano S, Sempere-Ortells JM, Soriano V, Benito JM.

J Immunol. 2010 Jul 15;185(2):982-9. doi: 10.4049/jimmunol.1000221. Epub 2010 Jun 11.

4.

HLA-DR-restricted peptides identified in the Nef protein can induce HIV type 1-specific IL-2/IFN-gamma-secreting CD4+ and CD4+ /CD8+ T cells in humans after lipopeptide vaccination.

Gahery H, Figueiredo S, Texier C, Pouvelle-Moratille S, Ourth L, Igea C, Surenaud M, Guillet JG, Maillere B.

AIDS Res Hum Retroviruses. 2007 Mar;23(3):427-37.

PMID:
17411376
5.

Broad and cross-clade CD4+ T-cell responses elicited by a DNA vaccine encoding highly conserved and promiscuous HIV-1 M-group consensus peptides.

Almeida RR, Rosa DS, Ribeiro SP, Santana VC, Kallás EG, Sidney J, Sette A, Kalil J, Cunha-Neto E.

PLoS One. 2012;7(9):e45267. doi: 10.1371/journal.pone.0045267. Epub 2012 Sep 18.

6.

Identification of novel consensus CD4 T-cell epitopes from clade B HIV-1 whole genome that are frequently recognized by HIV-1 infected patients.

Fonseca SG, Coutinho-Silva A, Fonseca LA, Segurado AC, Moraes SL, Rodrigues H, Hammer J, Kallás EG, Sidney J, Sette A, Kalil J, Cunha-Neto E.

AIDS. 2006 Nov 28;20(18):2263-73.

PMID:
17117012
7.

Immune activation and antibody responses in non-progressing elite controller individuals infected with HIV-1.

Bello G, Velasco-de-Castro CA, Bongertz V, Rodrigues CA, Giacoia-Gripp CB, Pilotto JH, Grinsztejn B, Veloso VG, Morgado MG.

J Med Virol. 2009 Oct;81(10):1681-90. doi: 10.1002/jmv.21565.

PMID:
19697415
8.

Clinical Control of HIV-1 by Cytotoxic T Cells Specific for Multiple Conserved Epitopes.

Murakoshi H, Akahoshi T, Koyanagi M, Chikata T, Naruto T, Maruyama R, Tamura Y, Ishizuka N, Gatanaga H, Oka S, Takiguchi M.

J Virol. 2015 May;89(10):5330-9. doi: 10.1128/JVI.00020-15. Epub 2015 Mar 4.

9.

Fine specificity and cross-clade reactivity of HIV type 1 Gag-specific CD4+ T cells.

Norris PJ, Moffett HF, Brander C, Allen TM, O'Sullivan KM, Cosimi LA, Kaufmann DE, Walker BD, Rosenberg ES.

AIDS Res Hum Retroviruses. 2004 Mar;20(3):315-25.

10.

HIV type 1 antigen-responsive CD4+ T-lymphocytes in exposed yet HIV Type 1 seronegative Ugandans.

Kebba A, Kaleebu P, Serwanga J, Rowland S, Yirrell D, Downing R, Gilmour J, Imami N, Gotch F, Whitworth J.

AIDS Res Hum Retroviruses. 2004 Jan;20(1):67-75.

PMID:
15000700
11.

Characterization of cross-reactive CD8+ T-cell recognition of HLA-A2-restricted HIV-Gag (SLYNTVATL) and HCV-NS5b (ALYDVVSKL) epitopes in individuals infected with human immunodeficiency and hepatitis C viruses.

Vali B, Tohn R, Cohen MJ, Sakhdari A, Sheth PM, Yue FY, Wong D, Kovacs C, Kaul R, Ostrowski MA.

J Virol. 2011 Jan;85(1):254-63. doi: 10.1128/JVI.01743-10. Epub 2010 Oct 27.

12.
13.

A new antigen scanning strategy for monitoring HIV-1 specific T-cell immune responses.

Malnati MS, Heltai S, Cosma A, Reitmeir P, Allgayer S, Glashoff RH, Liebrich W, Vardas E, Imami N, Westrop S, Nozza S, Tambussi G, Buttò S, Fanales-Belasio E, Ensoli B, Ensoli F, Tripiciano A, Fortis C, Lusso P, Poli G, Erfle V, Holmes H.

J Immunol Methods. 2012 Jan 31;375(1-2):46-56. doi: 10.1016/j.jim.2011.09.005. Epub 2011 Sep 22.

PMID:
21963950
14.

Proteome-wide analysis of HIV-specific naive and memory CD4(+) T cells in unexposed blood donors.

Campion SL, Brodie TM, Fischer W, Korber BT, Rossetti A, Goonetilleke N, McMichael AJ, Sallusto F.

J Exp Med. 2014 Jun 30;211(7):1273-80. doi: 10.1084/jem.20130555. Epub 2014 Jun 23.

15.

HIV-1-specific cytolytic T-lymphocyte activity correlates with lower viral load, higher CD4 count, and CD8+CD38-DR- phenotype: comparison of statistical methods for measurement.

Lubaki NM, Shepherd ME, Brookmeyer RS, Hon H, Quinn TC, Kashamuka M, Johnson M, Gottle R, Devers J, Lederman HM, Bollinger RC.

J Acquir Immune Defic Syndr. 1999 Sep 1;22(1):19-30.

PMID:
10534143
16.

Immunoprevalence of the CD4+ T-cell response to HIV Tat and Vpr proteins is provided by clustered and disperse epitopes, respectively.

Castelli FA, Houitte D, Munier G, Szely N, Lecoq A, Briand JP, Muller S, Maillere B.

Eur J Immunol. 2008 Oct;38(10):2821-31. doi: 10.1002/eji.200738072.

17.

Propagation of CD4+ T cells specific for HIV type 1 envelope gp120 from chronically HIV type 1-infected subjects.

Cohen S, Tuen M, Hioe CE.

AIDS Res Hum Retroviruses. 2003 Sep;19(9):793-806.

PMID:
14585210
18.

New CD4+ and CD8+ T cell responses induced in chronically HIV type-1-infected patients after immunizations with an HIV type 1 lipopeptide vaccine.

Gahery H, Daniel N, Charmeteau B, Ourth L, Jackson A, Andrieu M, Choppin J, Salmon D, Pialoux G, Guillet JG.

AIDS Res Hum Retroviruses. 2006 Jul;22(7):684-94.

PMID:
16831093
19.

Human immunodeficiency virus type 1 (HIV-1)-seronegative injection drug users at risk for HIV exposure have antibodies to HLA class I antigens and T cells specific for HIV envelope.

Beretta A, Weiss SH, Rappocciolo G, Mayur R, De Santis C, Quirinale J, Cosma A, Robbioni P, Shearer GM, Berzofsky JA, et al.

J Infect Dis. 1996 Feb;173(2):472-6.

PMID:
8568315
20.

Strong HIV-1-specific T cell responses in HIV-1-exposed uninfected infants and neonates revealed after regulatory T cell removal.

Legrand FA, Nixon DF, Loo CP, Ono E, Chapman JM, Miyamoto M, Diaz RS, Santos AM, Succi RC, Abadi J, Rosenberg MG, de Moraes-Pinto MI, Kallas EG.

PLoS One. 2006 Dec 20;1:e102.

Supplemental Content

Support Center